hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06360991 id: DBS for TR-OCD briefTitle: DBS for Treatment-resistant Obsessive-compulsive Disorder overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2028-12-31 date: 2029-12-31 date: 2024-04-11 date: 2024-04-11 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) implantation targeting the anteromedial region of subthalamic nucleus (amSTN), or nucleus accumbens (NAc), or bed nucleus of the stria terminalis (BNST), or ventral capsule/ventral striatum (VC/VS), or the ventral anterior limb of the internal capsule (vALIC) in patients with treatment-resistant obsessive-compulsive disorder (TR-OCD). conditions: Obsessive-Compulsive Disorder (OCD) studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Deep brain stimulation (DBS) measure: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): the change from baseline to 1 year in the Y-BOCS total score. measure: Yale-Brown Obsessive Compulsive Scale (Y-BOCS): remission, response, and partial response rate measure: Hamilton Anxiety Scale (HAMA): the change from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year in the HAMA total score. measure: Hamilton Depression Rating Scale (HAMD-17): the changes of HAMD-17 scores and its subscales from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year. measure: Pittsburgh Sleep Quality Index (PSQI): the change of PSQI from baseline to Week 2, Month 1, Month 3, Month 6, and Month 1. measure: Clinical Global Impression-Severity (CGI-S): the change from baseline to 2 weeks, 1 month, 3 months, 6 months, and 1 year in Clinical Global Impression-Severity (CGI-S) measure: Clinical Global Impression-Improvement (CGI-I): CGI-I score at Week 2, Month 1, Month 3, Month 6, and Month 12. measure: EuroQol-5 Dimension-level Scale (EQ-5D-5L): the change from baseline to Week 2, Month 1, Month 3, Month 6, and Month 12 in EQ-5D-5L. measure: Young Mania Rating Scale (YMRS): the change from baseline to Week 2, Month 1, Month 3, Month 6, and Month 12. measure: Safety as indicated by the number of Adverse Events Week 2, Month 1, Month 3, Month 6, and Month 12. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xuanwu Hospital, Capital Medical University city: Beijing zip: 100053 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06360978 id: docetaxel as a radiosenstizer briefTitle: Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06 date: 2027-06 date: 2024-04-11 date: 2024-04-11 name: Assiut University class: OTHER briefSummary: Head and neck cancer (HNC) is the seventh most common cancer globally, accounting for more than 660,000 new cases and 325,000 deaths annually. The overall incidence of HNC continues to rise, with a predicted 30% increase annually by 2030., this increase has been recorded across both developed and developing countries.
Approximately 90% of HNCs are squamous cell carcinoma . The major risk factors of head and neck squamous cell carcinoma (HNSCC) are tobacco and heavy alcohol use and human papillomavirus infection . There has been a significant decline in smoking in high-income countries during the last few decades, which has led to a sharp decline in smoking related HNSCC . While increase in global incidence of human papillomavirus (HPV)-associated or positive (+) HNSCC Head and neck squamous cell carcinoma (HNSCC) is a highly challenging cancer, despite the advancements in treatment, the overall prognosis for HNSCC remains poor, with a five-year survival rate of around 50%.
Chemoradiation is one of the treatment options for locally advanced head and neck cancers, the drug of choice for radiosensitization is cisplatin Although cisplatin-based chemoradiotherapy (CRT) is the standard of care for locally advanced head and neck squamous cell carcinoma (LAHNSCC), cisplatin is contraindicated in many patients because of age, diminished renal functions and hearing loss so docetaxel studied as an alternative radiosensitizer in this group.
The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC. conditions: Head and Neck Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Docetaxel measure: progression free survival measure: incidence of treatment adverse events measure: Overall survival (OS) sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360965 id: Shoufa2024-3-7045 briefTitle: Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain overallStatus: RECRUITING date: 2024-01-01 date: 2026-03-31 date: 2026-12-31 date: 2024-04-11 date: 2024-04-11 name: Beijing Hospital of Integrated Traditional Chinese and Western Medicine class: OTHER briefSummary: Chronic Pelvic Pain is one of the common gynecological symptoms, characterized by persistent and non periodic pain in the pelvic cavity and surrounding tissues. It is often seen as a sequelae of pelvic inflammatory diseases caused by the failure to receive timely and correct treatment. This study compares the effectiveness of warm meridians and relieve pain plaster in relieving the sequelae of pelvic inflammatory disease and chronic pelvic pain symptoms, and evaluates the safety of improved patches and traditional patches, further promoting it to community grassroots hospitals. conditions: Pelvic Inflammatory Disease conditions: Chronic Pelvic Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Improved warm meridians and relieve pain plaster name: Traditional warm meridians and relieve pain plaster name: Placebo plaster measure: Main symptoms (lower abdominal pain) improvement level (visual analogue scale) measure: TCM syndrome score scale measure: Local physical sign rating scale measure: Pelvic masses and fluid accumulation measure: EuroQol Five Dimensions Questionnaire measure: Recurrence of abdominal pain during 1-month menstrual cycle was followed up. sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Beijing Hospital of Integrated Traditional Chinese and Western Medicine status: RECRUITING city: Beijing country: China name: YuNa Liu role: CONTACT phone: 86-010-88223667 email: kjk882236672@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06360952 id: T23-03 briefTitle: A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-07-30 date: 2024-07-30 date: 2024-04-11 date: 2024-04-26 name: Tasso Inc. class: INDUSTRY name: The Leukemia and Lymphoma Society briefSummary: This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.
This investigation will include a minimum of 40 sample sets from unique patients. conditions: Leukopenia conditions: Leukocytosis conditions: Neutropenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Tasso+ CBC measure: Agreement between capillary and venous blood in the measurement of White Blood Cells and Absolute Neutrophil Count measure: Agreement between capillary and venous blood in the measurement of secondary biomarkers measure: Patient acceptance of Tasso device sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lineberger Comprehensive Cancer Center city: Chapel Hill state: North Carolina zip: 27599 country: United States lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06360939 id: ETH02659 briefTitle: Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease acronym: Radioablate overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-04-15 date: 2027-04-15 date: 2024-04-11 date: 2024-04-11 name: Western Sydney Local Health District class: OTHER name: University of Sydney name: National Heart Foundation, Australia briefSummary: The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:
* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care). conditions: Ventricular Tachycardia conditions: Cardiomyopathies conditions: Arrhythmias, Cardiac conditions: Ventricular Arrythmia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: SBRT name: CA measure: VT burden measure: Recurrent sustained VT measure: VT storm measure: Absolute VT burden measure: Serious Adverse Events (SAE) and Adverse Events of Special Interest (AESI) measure: ICD shocks measure: Hospitalization measure: All cause mortality measure: Cardiovascular Mortality measure: Composite outcome of VT recurrence/hospitalisation/death/ cardiac transplantation measure: Ventricular function measure: Quality of Life as per Short Form - 36 (SF-36) Score measure: Quality of Life as per Implantable Cardioverter Defibrillator Concerns Questionnaire (ICDC) score measure: Number of AADs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360926 id: 2024-A00526-41 briefTitle: Improvement Image Quality for SuperSonic® MACH Ultrasound System acronym: MACH IQ overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-05 date: 2024-04-11 date: 2024-04-11 name: SuperSonic Imagine class: INDUSTRY briefSummary: The aim of this Study is to collect radiologist feedback to support the further development and improvement of the imaging modes implemented on the embedded software in the SuperSonic® Ultrasound System (including the probe). conditions: Diagnosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: SuperSonic® Ultrasound System measure: Qualitative assessment of image quality sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360913 id: 2023/09AOU/346 briefTitle: Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases acronym: BUSARD overallStatus: RECRUITING date: 2024-01-03 date: 2028-01 date: 2028-01 date: 2024-04-11 date: 2024-04-12 name: Cliniques universitaires Saint-Luc- Université Catholique de Louvain class: OTHER briefSummary: The primary goal of this study is to establish a biobank of dried blood spots and urines from a large control cohort and collect several cohorts as large as possible of patients affected or suspected of being affected by rare diseases (mainly hereditary metabolic diseases) or by autism spectrum disorders.
Objectives Unravel new biomarkers for diagnosis (+/- explore the altered pathways...) Uncover and/or validate newborn screening biomarkers through retrospective analysis of preserved newborn DBS from confirmed patients (useful for first or second tier biochemical NBS testing!) Validation of LC-MS qTOF for metabolomics screening as first line diagnostic test (thousands of metabolites) using diagnostic algorithms (modified z-scores) \& continuous optimization by adding new cases and new controls in the database Generation of a biobank of urines and DBS from rare diseases (IEMs) \& from a large reference population useful for other research applications conditions: Inborn Errors of Metabolism conditions: Rare Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 3 groups:
3. Suspected patients (rare diseases) primaryPurpose: DIAGNOSTIC masking: NONE count: 2286 type: ESTIMATED name: High resolution mass spectrometry measure: Uncover new biomarkers in dried blood spots and urines samples able to improve the diagnosis of rare diseases sex: ALL minimumAge: 1 Day maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Universitaire des enfants Reine Fabiola (HUDERF-ULB) status: NOT_YET_RECRUITING city: Brussels zip: B-1020 country: Belgium name: Lionel Marcélis, MSc, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Aurélie Empain, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR name: Corinne De Laet, M.D., Ph.D. role: SUB_INVESTIGATOR name: Ebru Surgun, M.D. role: SUB_INVESTIGATOR name: Céline Morelli, M.D. role: SUB_INVESTIGATOR lat: 50.85045 lon: 4.34878 facility: Cliniques universitaires Saint Luc status: RECRUITING city: Brussels zip: B-1200 country: Belgium name: Joseph P. Dewulf, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR name: Marie-Cécile Nassogne, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR name: Xavier Stephenne, M.D., Ph.D. role: SUB_INVESTIGATOR name: Nicole Revencu, M.D., Ph.D. role: SUB_INVESTIGATOR name: Stéphanie Paquay, M.D. role: SUB_INVESTIGATOR lat: 50.85045 lon: 4.34878 facility: Institut de Pathologie et de Génétique (IPG) status: NOT_YET_RECRUITING city: Charleroi zip: B-6041 country: Belgium name: Dominique Roland, M.D. role: PRINCIPAL_INVESTIGATOR name: Damien Lederer, M.D., Ph.D. role: SUB_INVESTIGATOR name: Isabelle Maystadt, M.D., Ph.D. role: SUB_INVESTIGATOR lat: 50.41136 lon: 4.44448 facility: CHU Liege status: NOT_YET_RECRUITING city: Liège zip: B-4000 country: Belgium name: François-Guillaume Debray, MD PhD role: PRINCIPAL_INVESTIGATOR name: François Boemer, Pharm D PhD role: PRINCIPAL_INVESTIGATOR name: Caroline Dadoumont, MD role: SUB_INVESTIGATOR lat: 50.63373 lon: 5.56749 hasResults: False
nctId: NCT06360900 id: 2024P000849 briefTitle: Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Cognitive Behavioral Therapy in Functional Dyspepsia overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-03 date: 2029-03 date: 2024-04-11 date: 2024-04-11 name: Spaulding Rehabilitation Hospital class: OTHER briefSummary: The primary aims of this randomized, single-blinded, 2x2 sham-controlled trial are to 1) evaluate synergistic impact of 8-weeks of transcutaneous auricular vagus nerve stimulation (taVNS) + cognitive-behavioral therapy (CBT) on post-meal gut-brain communication; 2) determine the sequential relationship between treatment-associated changes in gastrointestinal-related anxiety and both clinical functional dyspepsia (FD) improvements and meal-induced physiological outcomes; 3) investigate whether post-treatment changes in gut-brain physiology mediate improvements in FD clinical outcomes. Using a fully non-invasive framework including gastric and brain magnetic resonance imaging (MRI) and taVNS, the investigators aim to evaluate the potential synergy of taVNS and CBT in FD, by assessing the gut-brain physiological response to prandial challenge, linking physiological with symptom improvements. conditions: Functional Dyspepsia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: taVNS name: CBT name: Education Control name: Sham taVNS measure: Nepean Dyspepsia Index (NDI) measure: Visceral Sensitivity Index (VSI) measure: Gastric peristaltic velocity sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360887 id: DRKS00030614 briefTitle: Management of Proximal Humerus Fractures in Adults: a Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-01-31 date: 2028-01-31 date: 2024-04-11 date: 2024-04-12 name: Regional Hospital of Bolzano class: OTHER briefSummary: Prospective patient registry examining the outcome of three different treatment methods for proximal humerus fractures in elderlies: conservative treatment, open and minimal invasive surgical treatment. conditions: Shoulder Fractures studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 351 type: ESTIMATED name: Conservative name: ORIF name: CRPP measure: Oxford Shoulder Score measure: The visual analogue scale measure: Rate of complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Academic Hospital of Bolzano (SABES-ASDAA) city: Bolzano state: Alto Adige zip: 39100 country: Italy name: Malte Nikolas Witte, Dr. role: CONTACT phone: 00393885787726 email: maltewitte@posteo.de lat: 46.49067 lon: 11.33982 hasResults: False
nctId: NCT06360874 id: ND003-I-06 briefTitle: A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-02 date: 2024-04-11 date: 2024-04-11 name: Shenzhen NewDEL Biotech, Co., Ltd class: INDUSTRY name: Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. briefSummary: The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: ND-003 40mg name: ND-003 placebo 40mg name: ND-003 80mg name: ND-003 placebo 80mg name: ND-003 160mg name: ND-003 placebo 160mg name: ND-003 240mg name: ND-003 placebo 240mg name: ND-003 300mg name: ND-003 placebo 300mg name: MAD_ND003_Dose 1 name: MAD_placebo_Dose 1 name: MAD_ND003_Dose 2 name: MAD_placebo_Dose 2 name: MAD_ND003_Dose 3 name: MAD_ placebo_Dose 3 name: Food effect_Cohort 1 name: Food effect_Cohort 2 measure: Adverse Events (AE) measure: maximum concentration (Cmax) measure: Time to maximum concentration (Tmax) measure: Elimination Half-life (t1/2) measure: Clearance (CLz/F) measure: AUC from time 0 to last time of quantifiable concentration (AUC0-t) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06360861 id: 1400-1-233-51589 id: IR.TUMS.MEDICINE.REC.1400.197 type: OTHER_GRANT domain: Tehran University of Medical Sciences briefTitle: Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis acronym: MS overallStatus: COMPLETED date: 2019-07-23 date: 2024-03-04 date: 2024-03-06 date: 2024-04-11 date: 2024-04-11 name: Tehran University of Medical Sciences class: OTHER briefSummary: To assess the safety and of a single dose of IV infusion of placenta derived Mesenchymal Stem Cells (PLMSCs) in patients with secondary progressive Multiple Sclerosis (SPMS) disease.
nctId: NCT06360848 id: IRB00001192 briefTitle: Surgical Treamtment of Pseudarthrosis of the Humerus (Study of a Series of 53 Cases) overallStatus: COMPLETED date: 2005-01-01 date: 2021-01-01 date: 2021-01-01 date: 2024-04-11 date: 2024-04-11 name: Ibn Jazzar Hospital class: OTHER briefSummary: Pseudarthrosis of the humerus is a serious complication of humerus fractures, of particular interest to subjects young working people with pseudoarthrogenic risk factors (tobacco++). It represents a real problem therapeutic given the long period of treatment, its disabling socio-professional repercussions and the cost which resulting.
The aim of our work is to evaluate the anatomical and functional results of different surgical techniques. used. conditions: Humerus Fracture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 53 type: ACTUAL name: surgery measure: Distribution of atrophic pseudarthrosis according to technique surgical procedure used (in Number of patients) measure: Distribution of hypertrophic pseudarthrosis according to technique surgical procedure used (in Number of patients) measure: Time to consolidation depending on the type of pseudarthrosis (in months) measure: Average Constant score postoperatively according to the means of restraint sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360835 id: IRB00001193 briefTitle: Our Experience in the Management of Therapeutic Failures of Fractures of the Proximal End of the Femur (About 35 Cases) overallStatus: COMPLETED date: 2015-01-01 date: 2021-12-01 date: 2021-12-02 date: 2024-04-11 date: 2024-04-11 name: Ibn Jazzar Hospital class: OTHER briefSummary: Osteosyntheses employed in treating fractures at the upper end of the femur play a critical role in facilitating a swift recovery by minimizing immobilization periods and enabling early rehabilitation of the affected joints, thereby promoting a speedy return to normal walking function.
However, it is essential to note that THA subsequent to complications arising from proximal femur osteosynthesis presents a higher incidence of both intraoperative and postoperative complications compared to the implantation of primary total hip prostheses. Thus, while osteosynthesis remains a valuable intervention for femur fractures, careful attention to material selection and postoperative management is crucial in optimizing patient outcomes and minimizing complications. conditions: Proximal Femur Fractures studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 35 type: ACTUAL name: total hip arthroplasty measure: Surgical Approach measure: Preparation of the Patient measure: Anesthesia measure: Type of Surgical Revision measure: Types of Prosthesis measure: Age Distribution measure: Distribution by Sex measure: Distribution According to Affected Side measure: Distribution According to Circumstances of Trauma sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IBN jazzar hospital city: Kairouan zip: 3190 country: Tunisia lat: 35.6781 lon: 10.09633 hasResults: False
nctId: NCT06360822 id: 19317 briefTitle: Increasing Equity in Lung Cancer Screening acronym: LUCARE overallStatus: RECRUITING date: 2023-12-01 date: 2027-02-01 date: 2027-02-01 date: 2024-04-11 date: 2024-04-11 name: Indiana University class: OTHER name: Eskenazi Health briefSummary: The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement. conditions: Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 144 type: ESTIMATED name: ED-LCS measure: Rate of patients receive Lung Cancer Screening measure: Patients ratings of intervention sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eskenazi Health status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States name: Nicholas Pettit, MD role: CONTACT phone: 317-962-5975 email: nrpettit@iu.edu lat: 39.76838 lon: -86.15804 hasResults: False